Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Clinical Trials
SUMMIT™ Trial
Enrollment Complete
Learn More
Press Releases
Feb 02, 2023
Satsuma Pharmaceuticals to Participate in the Virtual SVB Securities Global Biopharma Conference
Read More
Dec 20, 2022
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Read More
